The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir, Ledipasvir, and Ribavirin in Patients with Chronic Hepatitis C, Genotype 1, Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis

Background. The recommended therapy for patients with chronic hepatitis C (CHC), genotype 1, who have cirrhosis and have failed prior therapy is 12 weeks of sofosbuvir (SOF), ledipasvir (LDV), and ribavirin (RBV). This recommendation is based on expert opinion, and the efficacy of 12 weeks of SOF/LD...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Can J Gastroenterol Hepatol
Egile Nagusiak: Stokes, William, Fenton, Carol, Clement, Fiona, James, Matthew, Ronksley, Paul, Tang, Karen L.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Hindawi 2017
Gaiak:
Review Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5358456/
https://ncbi.nlm.nih.gov/pubmed/28367429
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2017/6468309
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak